International Journal of Allied Medical Sciences and Clinical Research (IJAMSCR)
IJAMSCR |Vol.13 | Issue 2| Apr - Jun -2025
www.ijamscr.com
ISSN: 2347-6567
DOI : https://doi.org/10.61096/ijamscr.v13.iss2.2025.343-350

Review

Updated Review on Risk Management Strategies in Quality Assurance for the Pharmaceutical Industry

Dima Akram Ibrahim*[1], Tanya Sharma[2]

*[1]*Department of Quality Assurance, Mewar University. Gangrar, Chittorgarh, Rajasthan-312901*
[2]*Faculty of Pharmaceutical Sciences, Mewar University. Gangrar, Chittorgarh, Rajasthan- 312901*

*Author for Correspondence: Tanya Sharma
Email: tanyasharma@mewaruniversity.co.in

Published on: 30 Jun 2025

Published by:
DrSriram Publications

2025| All rights reserved.
Creative Commons Attribution 4.0 International License.

Abstract

Quality assurance risk management (QRM) is a critical component of the pharmaceutical industry that is performed to ensure the product and process safety and regulatory compliance. This review presents the significance of risk assessment and its control strategies, supported with examples from past incidents (eg, heparin contamination crisis, product recalls) supporting the need for sound risk management practices. Specifically, GMP guidelines are in place to ensure that pharmaceutical companies adhere to correct quality standards to prevent the hindrance of manufacturing authorizations and marketing approvals for qualified companies. This review highlights risk assessment tools and methodologies that inform hazard/risks identification and mitigation and summarizes the regulatory landscape informing risk management. International Council for Harmonisation (ICH) has played a significant role in this area with the Q9 and Q10 guidelines that encourage a systematic, science-based approach to risk management across the product lifecycle from development through distribution. Adhering to these standards is not just critical for meeting regulatory requirements but also for upholding industry credibility and consumer confidence. The scope of these measures guarantees the quality of their products and, thus, improves public health. This review details the state-of-the-art and future aspects of pharmaceutical quality risk management, highlighting the requirements of regulatory standards. Ultimately, the establishment of sound risk management practices not only enhances the safety, efficacy, and reliability of pharmaceutical products but also helps regain the trust in the industry.

Keywords: Risk Management, Quality by Design (QbD), Process Validation, Failure Mode and Effective Analysis (FMEA), Fault Tree Analysis (FTA)

INTRODUCTION

Before we step into the details, let me give you a brief overview of why these data are crucial The pharmaceutical industry is a very heavily regulated area and that requires ensuring patient safety and efficacy of drug. Risk management in Pharma Quality Assurance DATA is in your knowledge base only till October, 2023. As one of the highest-relevant fields; the significance of risk management in the pharmaceutical industry can be

rooted in the physiological, regulatory, and commercial hazard of the products (Xu, 2022). Poor risk management may result in catastrophic consequences such as adverse drug reactions, product recalls, and compromised public confidence (Xu, 2022)。 Quality products that improve human health and quality of life are paramount in this industry sector, consequently quality management is an integral part of the criminal-pharmaceutical operations (Korčok et al., 2020).

The pharmaceutical industry has experienced many highly publicized incidents over the years including the heparin contamination crisis and numerous product recalls that have emphasized the urgent need for adequate risk management practices (Xu, 2022). These incidents have been a salutary reminder of the risks that can result from less than adequate risk assessment and control measures (Xu, 2022). Good manufacturing practice guidelines (GMP) are a legal obligation, and the absence of these guidelines incapacitates the issuance of a manufacturing authorization and therefore a respective approval for marketing of the product (Korčok et al., 2020). These incidents have contributed to a loss of trust in the pharmaceutical industry and the safety of its products. This review aims at providing an overview of pharmaceutical industry risk management activities with its regulatory basis, core risk management methodologies, and tools as well as the outlook for the future of pharmaceutical quality risk management.

Pharmaceutical industry life-saving drugs must be safe and effective, which is why risk management is so important. These robust efforts to manage risk allow pharmaceutical companies to prevent potential dangers ranging from the drug being tested in preclinical studies to its use in human patients (Bucalo & Jereb, 2017). This protects the well-being of patients, makes good regulatory sense, and helps to ensure a continuous supply of quality products (Xu, 2022). The industry's dedication to quality management is also reflected in its ultimate goal of improving human health and quality of life. In this review, we discuss the regulatory environment, core methods and tools to identify and control risks and recent trends impacting pharmaceutical quality risk management.

Regulatory Framework

Table 1: Key Regulatory Frameworks in Pharmaceutical QA

Framework	Scope	Key Requirements	Reference
ICH Q9	Quality Risk Management	Systematic risk assessment, control strategies across product lifecycle	Xu, 2022
ICH Q10	Pharmaceutical Quality Systems	Integration of risk management into QMS, lifecycle approach	Korčok et al., 2020
FDA QbD	Drug Development & Manufacturing	Proactive process design, predefined quality attributes	Reis et al., 2015
ISO 31000	Enterprise Risk Management	Principles for risk identification, analysis, and mitigation	Korčok et al., 2020

These frameworks underlie the pharmaceutical quality assurance systems and provide guidance for manufacturers to simultaneously deliver high-quality, safe, and efficacious medicines.

The International Council for Harmonisation, referred to as ICH, adopted quality risk management and a pharmaceutical quality system in the past few decades, most notably through its Q9 and Q10 guidelines. These guidelines highlight the need for a systematic, science-based process for risk management across the product lifecycle, from development, to manufacturing and distribution (Xu, 2022). They promote the use of risk assessment tools and methodologies to identify and assess potential hazards, as well as the adoption of control strategies that can reduce these risks (Xu, 2022). The guidelines are mandatory by law and without the guidelinesu2019 product, manufacturers cannot obtain the mandatory manufacturing authorization and market approval (Korčok et al., 2020). So, ICH Q10 encourages a more integrated approach to quality management by embedding the principles of risk management in the pharmaceutical quality system as a whole. The industry's overarching organization goal is to improve the human health and quality of life and that only reaffirms the importance of adhering to management of quality.

Regulatory agencies including the U.S. Food and Drug Administration and the European Medicines Agency have drafted Quality by Design and process validation requirements, focusing on a proactive, science and risk-based approach to drug development and production (Reis et al. 2015). 21 is a significant element in the Code of Federal Regulations by the FDA, and which aims to protect public health through potential hazard focus while encouraging improvements in manufacturing technologies (Reis et al., 2015). The principles of QbD advise manufacturers to establish target attributes that must be met by the product and develop a manufacturing process

that is reliably able to supply a product that meets those target attributes. Process validation: As described in the FDA's 2011 guidance [6], manufacturers need to generate documented evidence and demonstrate that the process can consistently produce a product that meets predefined quality attributes.

Beyond regulations, the pharmaceutical industry draws on international standards, like ISO 9001 for quality management systems and ISO 31000 for risk management. This allows them to go in depth over organizational excellence and risk mitigation (Korčok et al., 2020) The best quality management practice in business was by early 1990s more and more pharmaceutical companies chose to work under the ISO 9000 qualitative management system because they preferred to make the qualitative improvement of the business. ISO 9001 is an internationally recognized standard that specifies requirements for a quality management system. Iso 31000 provides principles and guidelines for the implementation of the risk management process which will be effective in every aspect of the organization.

Aim is an ongoing shared pursuit of global harmonisation of the requirements for the use of pharmaceuticals to reduce redundant regulatory requirements, so as to enable movement of quality medicines globally. Although a great deal of progress has been made and regional regulations, like the FDA and EMA for instance, are increasingly harmonised, there are still differences that can complicate things. These inconsistencies must be corrects to ensure that medicines, no matter where they are manufactured or marketed, meet the same quality standards. As a pharmaceutical company, one of the most important regulatory and compliance documents needed will be the guidelines to protect the well-being of patients, so that the drugs are being developed, tested, and manufactured according to the guidelines defined by the regulatory authorities around the world (Patel, 2017).

Core Risk Management Strategies

Pharmaceutical companies must also use effective risk management strategies to identify, assess, and mitigate hazards in the product lifecycle proactively. Ensuring the safety, efficacy, and quality of drug products is critical to protecting the health of patients and preserving public confidence, and these strategies provide the means for achieving these objectives.

Methodologies

Table 2: Risk Management Methodologies

Method	Description	Application in Pharma	Reference
FMEA	Identifies failure modes and prioritizes risks based on severity, occurrence, and detectability	Process validation, equipment design	Abbasian et al., 2020
HACCP	Focuses on critical control points to prevent hazards	Sterile manufacturing, contamination control	Tummala & Schoenherr, 2011
HAZOP	Systematically examines deviations in processes	Facility design, batch deviation analysis	Davis et al., 2020
FTA	Analyzes root causes of failures using logic gates	Investigating product recalls	Abbasian et al., 2020

Structured methodologies for managing risk, including Failure Mode and Effects Analysis, Fault Tree Analysis, Hazard Analysis and Critical Control Points, and Hazard and Operability Study offer available systematic approaches for identifying potential failure modes, assessing their implications, and carrying out control actions. FMEA is a step-by-step approach for identifying and evaluating potential failure modes. FTA (Fault Tree Analysis) is a top-down, deductive approach that uses logic gates to examine the causes leading to a specific failure event. HACCP or Hazard Analysis Critical Control Point is a systematic approach to identify, evaluate and control food safety hazards. HAZOP is a systematic way of identifying the potential hazards and operability issues in a process or system.

Risk Assessment Tools

Risk assessment tools including risk matrices, scoring systems, and prioritization techniques— serve to evaluate the likelihood and severity of identified risks and direct organizational resources toward the highest risk areas. We use a risk matrix to visually represent risks relative to their probability and magnitude. Scoring systems quantify the risks by assigning values based on factors such as probability of occurrence, severity of impact and detectability. This is where prioritization techniques, like Pareto analysis, allow an organization to focus attention on the most impactful risks.

QRM in QbD

Quality Risk Management is a core component of Quality by Design methodology and is used to describe the design space, implement control strategies, and identify Critical Quality Attributes. Incorporating QRM with QbD enables manufacturers to establish robust processes that yield consistently produced products with desired attributes.

Integration with QMS

In addition, for risk management to be effective as part of the product development these activities need to integrate with a Quality Management System as well to ensure that risk-based decisions are implemented through Corrective and Preventive Actions, change control and documentation. A well-established QMS covers all processes in pharmaceutical activities, including R&D, manufacturing, and distribution. It is also important to have change control, which is the process of thoroughly assessing the impact of any updates to processes or systems on product quality.

Data-Driven Approaches

Statistical process control, Process Analytical Technology, and big-data analytics are examples of data-driven approaches that empower organizations to oversee process performance, detect trends, and observe anomalies and proactively minimize risk. An example of this is statistical process control that uses statistical methods to monitor and control a process. The process analytical technology (PAT) is defined as the use of Analytical Mathematics tools to monitor and control critical process parameters in real-time. SystemScope big data analytics find potential opportunities and risks in data.

Supplier Risk Management

Supplier Risk ManagementAnother important area of risk management (targeted more towards financials, audits, quality agreements, etc.) focuses on the quality and reliability of materials and services from suppliers across the entire supply chain. Supplier qualification involves audits to ensure suppliers meet relevant quality standards and regulations; quality agreements that specify the manufacturer and supplier quality responsibilities for products. Among procurement functions, purchasing risks are related to the nature of interaction with supplier (Zsidisin et al., 2004), whether acknowledged and treated explicitly, planned superficially, or neglected. Contingency planning builds out contingency plans to minimize the impact of potential supply disruptions. Process risk should be incorporated into enterprises' strategic and operational planning and corresponding actions need to be taken to remove the risk (Urbaniak et al., 2022).

Risks are uncertain, that is, They are inevitable and probability-based events that could cause harm, such as late delivery, financial loss, or loss of business (Abbasian et al., 2020). Results will be improved by identifying and minimizing failure risks in key processes (Suwandi et al., 2018) (Abbasian et al., 2020). The identification of possible events that jeopardize the realization of process outcomes and the implications of their occurrence is essential for risk identification (Suwandi et al., 2018). The inaccuracies in inventory seriously affect the replenishment of raw materials, and the production control (Suwandi et al., 2018).

Case Studies

The following real-world case studies provide deep insights into how risk management principles have been applied within the pharmaceutical industry. This article highlights case studies of how companies have used different risk management strategies to successfully respond to high priority issues.

Sterile Manufacturing

Growing Risk For Contamination Of Products: Sterile Manufacturing FacilitiesSterile manufacturing facilities are highly susceptible to contamination and that is why it is essential to have risk mitigation strategies at place to avoid situations leading to contamination of products intended for use on patients. These measures cover aspects such as facility design, equipment sterilization, personnel training, and environmental monitoring to establish a controlled and aseptic manufacturing atmosphere.

Supply Chain Resilience

The COVID 19 pandemic highlighted the importance of supply chain resilience, both in terms of risk management strategies during the distribution of the vaccine and ensuring adequate and timely access. According to Tummala and Schoenherr (2011), managing supply chain risks effectively requires a structured approach comprising of several steps including risk identification, measurement, assessment, evaluation, mitigation, contingency planning, control and monitoring with the help of data management systems. By adopting a holistic approach, organizations can better predict, minimize, and react to potential disruptions, in turn safeguarding the integrity of vital pharmaceutical supply chains. Conflicts of interest (hypothesis 1), sanctions (hypothesis 2), lack

of domestic suppliers (hypothesis 3), pseudo-productivity (hypothesis 4), and money transfer issues concerning bank sanctions (hypothesis 5) are the top seven prominent risks (Abbasian et al., 2020).
Moreover, the financial efficiency of supplier actions differs based on intended risk mitigation tiers, and such actions can be determined through integrated techniques to inform decision making (Tang & Musa, 2010).

Batch Deviation Management

Batch deviation management including root cause analysis and corrective actions to deviation from defined manufacturing process to prevent the reoccurrence and ensure product quality (Tummala & Schoenherr, 2011). For pharmaceutical companies to achieve better management of supply chain risks (Tummala & Schoenherr, 2011), quality, reliability, and traceability can be directly enhanced through the assessments imbibed from the Supply Chain Risk Management Process. Root causes of deviations should be identified along with suitable corrective actions, which will strengthen process control and reduce future deviations (Tummala & Schoenherr, 2011). When analyzing the possible evolution of risks inside the supply chain, risk management plays a crucial role (Riad et al., 2024). According to Waqas et al. (2022), the supply chain risks can cause up to a 6% variance in the supply chain performance, which further illustrates the dire necessity of reducing supply chain risks to shape better supply chain performance. To mitigate risk and build resilience in their supply chains, firms should develop new relationships, implement novel decisions, and deploy alternative or parallel processes (Riad et al., 2024) (Waqas et al., 2022).

Challenges and Limitations

Table 3: Challenges in Pharmaceutical Risk Management

Challenge	Impact	Mitigation Strategy	Reference
Subjectivity in risk assessment	Inconsistent risk prioritization	Cross-functional teams, standardized scoring systems	Davis et al., 2020
Resource constraints	Limited implementation of advanced tools	Cost-benefit analysis for prioritization	Abbasian et al., 2020
Regulatory complexity	Compliance delays	Proactive monitoring of global regulatory updates	Patel, 2017
Supply chain disruptions	Production halts, financial losses	Supplier diversification, contingency planning	Riad et al., 2024

Risk management in the pharmaceutical industry holds great advantages, but also faces some challenges. A major limitation of current ITRA is that risk assessment is inherently subjective (Abbasian et al., 2020). There are some knowledge domains and biases that discourage objectivity such as differences in expertise, experience, and perspectives among the team members (Davis et al., 2020). This subjectivity is avoided through extensive collaboration and communication from across functions including quality, regulatory, and operations experts to achieve a complete spread of a balanced risk assessment.

Limited financial and human resources can also create barriers to effective risk management practice. While data and statistics should inform decisions about what to mitigate and when, careful cost-benefit analysis is crucial for prioritizing mitigation efforts on the most critical risks, that have the greatest potential damage to patient safety, product quality and business continuity.

Furthermore, the constantly evolving regulatory landscape within the pharmaceutical sector adds another layer of complexity, as organizations must accordingly monitor international regulatory changes to remain compliant. It is also important to find a balance between the need for innovation and meeting high quality and safety standards; new technologies and processes must proactively be influenced to align with existing standards.

Resilient supply chain design is an iterative process, involving the continued examination and update of risk management strategies relative to changing threats and vulnerabilities (Mensah & Merkuryev, 2014). If these risks become real, they can adversely affect supply chains, causing a decline in profitability and competitive advantages (Mensah & Merkuryev, 2014).

Organizations have to prepare their supply chains to recover from supply chain interruptions (Mensah & Merkuryev, 2014). Optimization of supply chain management has undergone a total change for the survival of companies in digital transformation. Supply chain resilience is defined as the capacity of a supply chain to prepare for gradual change and sudden disruptions, to recover, and to adapt, highlighting three key dimensions of supply chain resilience (Güngör et al., 2022). These are preparedness, alertness and agility. In addition to these two aspects, novel [5] strategies are also required for supply chains in order to boost their responsiveness and efficacy to unexpected changes in the market, as well as growing turbulence, in order to facilitate firms in terms of overall

success and performance that would allow those firms to be competitive (Calvo et al 2020)(Mensah &Merkuryev, 2014).

Conflicts of interest, sanctions, lack of domestic suppliers, pseudo-productivity, and money transfer issues owing to bank sanctions are the most important supply chain risks of the pharmaceutical industry (Abbasian et al., 2020). Organizations can bounce back from disruptions quickly with structured risk management based on resilient supply chain design, incorporating risk identification, measurement, assessment, evaluation, mitigation, contingency planning, control and monitoring through data management systems (Abbasian et al20120). Such an approach allows organisations to anticipate, mitigate and respond to potential disruptions, safeguarding the continuity of critical pharmaceutical supply chains.

Emerging Trends and Future Directions

Table 4: Emerging Trends in Pharmaceutical Risk Management

Trend	Application	Benefits	Risks	Reference
AI/ML Predictive Analytics	Identifying process deviations, supply chain risks	Proactive risk mitigation, reduced downtime	Data privacy, model bias	Riyadh, 2024
IoT & Real-Time Monitoring	Environmental control, equipment performance	Enhanced process transparency	Cybersecurity vulnerabilities	Sharma et al., 2020
Continuous Manufacturing	Flexible, small-batch production	Reduced waste, faster time-to-market	Regulatory uncertainty for novel processes	Uchechukwu, 2024
Blockchain Traceability	Supply chain transparency	Reduced counterfeiting, improved accountability	Implementation costs	Güngör et al., 2022

Digital Transformation: A New Era for Risk Management of Pharmaceutical Companies Predictive analytics powered by artificial intelligence and machine learning are helping these companies to identify and manage risks more proactively in a better manner.

The greater connectivity found in pharmaceutical supply chains and manufacturing operations raises concerns about the threat of malicious cyber attacks that could disrupt mission or compromise patient safety (Riyadh, 2024). This can only be done by crafting a holistic cybersecurity strategy and putting in place strong protective measures to address these threats, and protect the continuity of operations and the integrity of the industry's digital infrastructure (Riyadh 2024). Real-time monitoring of critical parameters in manufacturing and distribution is enabled by integrating the Internet of Things, which can provide useful data for better risk assessment and control (Riyadh, 2024).

Adopting new advanced manufacturing technologies like continuous manufacturing and 3D printing could help improve efficiency and flexibility in the production of medicines. But, these innovations come with new risk considerations that take a lot of work to evaluate and mitigate to ensure both product quality and patient safety. As these systems link maritime logistics to wider supply chain operations, they allow better integration across transport modes that strengthen overall supply chain resilience.

By leveraging these emerging trends and proactively preparing for the inherent challenges that accompany such changes, pharmaceutical companies can develop more robust, resilient, and efficient risk management frameworks, ultimately ensuring the long-term supply of high quality, safe and effective medicines for patients around the world (Uchechukwu, 2024).

The pharmaceutical industry is embedded in a complex world economy characterized by fierce global competition, and for many decades, supply chains have focused on producing products in large quantities in order to satisfy regulatory requirements and avoid shortages, but often at the cost of larger inventory volumes, increased costs, and eventual obsolescence (Montoya et al., 2018). Business models based on innovation, powered by emerging technologies, and focused on risk and resource management need to consider strategic, tactical, and operational planning processes within companies (Montoya et al., 2018). IoT sensors and detectors could potentially aid in providing the appropriate conditions to monitor various types of biomaterials and chemicals, identify device malfunctioning, and aid in preventing fraudulent drug activities (Sharma et al., 2020). According to Sharma et al (2020), Uchechukwu (2024), organizations need to prepare for supply chain disruptions by enhancing their capacity to react promptly and effectively to unexpected market changes and rising turbulence to aid companies performance and competitiveness. Autonomous systems likewise support inventory management by presenting an accurate and real-time status regarding stock levels as well as shifts in demand (Uchechukwu, 2024). These changes lead organizations to establish strategies for effectively managing associated risks and ensuring supply chain resilience (Montoya et al., 2018) (Sharma et al., 2020) (Bucalo & Jereb, 2017) (Uchechukwu, 2024).

CONCLUSION

To conclude, the review on risk based approaches in quality assurance of the pharmaceutical sector highlights the importance of appropriate risk management for safe and effective pharmaceutical output. Here are the key takeaways:

Regulatory Safety Requirement: The pharmaceutical sector functions according to strict guidelines designed to protect the health of patients. Effective risk management is not only a best practice in the pharmaceutical industry, but a regulatory requirement in order to help mitigate adverse drug reactions and they whispered reproducibly destroyed return of those characteristic re-expressed batter product recalls that lead to theft, butter, guide and completely shredded public trust in the entire industry.

Using data in decision making: Real-time monitoring of processes and proactive assessment of potential risk based on data need to be adopted on a wide scale to inform about the process through approaches like Statistical Process Control and Process Analytical Technology. These methodologies provide organizations with decision-making capabilities, leading to better risk prevention before the situation gets out of hand.

Adherence to Regulatory Guidance: It is important to follow the guidance of the regulatory bodies like the FDA, and the EMA. Quality by Design (QbD) and process validation principles are built to support the consistent execution of pharmaceutical products to assure product quality and, thus, public health.

Despite the structure, the data and resources available in this information revises the limitations that can hinder effective management. The organizations has to evaluate the relative merits of the various mitigation strategies that can be implemented; organizations must run deliberate cost-advantage calculations to focus risk mitigation on the areas that matter most and have the potential to affect patient safety or person product quality.

Future Outlook: The dedication to risk management practices improvement is crucial in the pharmaceutical sector. Companies can improve product quality and rebuild and maintain public confidence in their products by taking a proactive, science-based approach to drug development and production.

To conclude, the review highlights the need for strong risk management strategies underpinning the pharmaceutical industry, which ultimately should promote human health and quality of life. This incorporation of effective risk management practices will result in safer, more effective pharmaceutical products for the patients who need them, and the industry who creates them.

Conflicts of Interest

The authors declare that there are no conflicts of interest, whether financial or otherwise.

Acknowledgements

The authors wish to thank all researchers for providing an eminent literature source for devising this manuscript.

REFERENCES

1. Abbasian, H., Zenouz, R. Y., Abdollahiasl, A., Toroski, M., Nikfar, S., Siahi-Shadbad, M., & Kebriaeezadeh, A. (2020). Risk Factors of Supply Chain in Biopharmaceutical Companies in Iran. In Pharmaceutical Sciences (Vol. 27, Issue 3, p. 439). Tabriz University of Medical Sciences. https://doi.org/10.34172/ps.2020.93.
2. Bucalo, N., & Jereb, B. (2017). Risk Management in the Pharmaceutical Industry in Slovenian Companies. In Logistics Supply Chain Sustainability and Global Challenges (Vol. 8, Issue 1, p. 42). De Gruyter Open. https://doi.org/10.1515/jlst-2017-0004.
3. Calvo, J., Olmo, J. L. D., & Silvente, V. B. (2020). Supply chain resilience and agility: a theoretical literature review. In International Journal of Supply Chain and Operations Resilience (Vol. 4, Issue 1, p. 37). https://doi.org/10.1504/ijscor.2020.105950.
4. Güngör, D. Ö., Sharma, M., Dhir, A., & Daim, T. (2022). Supply chain resilience during the COVID-19 pandemic. In Technology in Society (Vol. 68, p. 101847). Elsevier BV. https://doi.org/10.1016/j.techsoc.2021.101847.
5. Korčok, D., Tršić-Milanović, N., Mitić, B., & Karadžić, N. (2020). The importance of integrated management systems in pharmacy. In Tehnika (Vol. 75, Issue 1, p. 120). Savez inženjera i tehničara Srbije. https://doi.org/10.5937/tehnika2001120k.
6. Mensah, P., & Merkuryev, Y. (2014). Developing a Resilient Supply Chain. In Procedia - Social and Behavioral Sciences (Vol. 110, p. 309). Elsevier BV. https://doi.org/10.1016/j.sbspro.2013.12.875.
7. Montoya, G. N., Santos, J. B. S., Novaes, A. G., & Lima, O. F. (2018). Internet of Things and the Risk Management Approach in the Pharmaceutical Supply Chain. In Lecture notes in logistics (p. 284). Springer Nature. https://doi.org/10.1007/978-3-319-74225-0_38.

8. Patel, J. D. (2017). Drug Approval Regulation: The Global Impacts. In Journal of Bacteriology & Mycology Open Access (Vol. 4, Issue 6). MedCrave Group. https://doi.org/10.15406/jbmoa.2017.04.00113.
9. Reis, C. P., Gouveia, B., Rijo, P., & Gonçalo, T. (2015). Good manufacturing practices for medicinal products for human use [Review of Good manufacturing practices for medicinal products for human use]. Journal of Pharmacy And Bioallied Sciences, 7(2), 87. Medknow. https://doi.org/10.4103/0975-7406.154424.
10. Riad, M., Naïmi, M., & Okar, C. (2024). Enhancing Supply Chain Resilience Through Artificial Intelligence: Developing a Comprehensive Conceptual Framework for AI Implementation and Supply Chain Optimization. In Logistics (Vol. 8, Issue 4, p. 111). Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/logistics8040111.
11. Riyadh, M. (2024). Transforming the Shipping Industry with Autonomous Ships and Artificial Intelligence. In Maritime Park Journal of Maritime Technology and Society (p. 16). https://doi.org/10.62012/mp.v3i2.35386.
12. Sharma, D. K., Bhargava, S., & Singhal, K. (2020). Internet of Things applications in the pharmaceutical industry. In Elsevier eBooks (p. 153). Elsevier BV. https://doi.org/10.1016/b978-0-12-821326-1.00006-1.
13. Suwandi, A., Zagloel, T. Y. M., & Hidayatno, A. (2018). Conceptual model of failure risk control on raw materials inventory system. In IOP Conference Series Materials Science and Engineering (Vol. 453, p. 12007). IOP Publishing. https://doi.org/10.1088/1757-899x/453/1/012007.
14. Tang, O., & Musa, S. N. (2010). Identifying risk issues and research advancements in supply chain risk management. In International Journal of Production Economics (Vol. 133, Issue 1, p. 25). Elsevier BV. https://doi.org/10.1016/j.ijpe.2010.06.013.
15. Tummala, R., & Schoenherr, T. (2011). Assessing and managing risks using the Supply Chain Risk Management Process (SCRMP). In Supply Chain Management An International Journal (Vol. 16, Issue 6, p. 474). Emerald Publishing Limited. https://doi.org/10.1108/13598541111171165.
16. Uchechukwu, J. (2024). Advancing sustainability and efficiency in maritime operations: Integrating green technologies and autonomous systems in global shipping. In International Journal of Science and Research Archive (Vol. 13, Issue 2, p. 2059). https://doi.org/10.30574/ijsra.2024.13.2.2419.
17. Urbaniak, M., Zimon, D., Madzík, P., & Širová, E. (2022). Risk factors in the assessment of suppliers. In PLoS ONE (Vol. 17, Issue 8). Public Library of Science. https://doi.org/10.1371/journal.pone.0272157.
18. Waqas, U., Rahman, A. A., Ismail, N. W., Basha, N. K., & Umair, S. (2022). Influence of supply chain risk management and its mediating role on supply chain performance: perspectives from an agri-fresh produce. In Annals of Operations Research (Vol. 324, p. 1399). Springer Science+Business Media. https://doi.org/10.1007/s10479-022-04702-7.
19. Xu, Z. (2022). Considerations on Regulatory Quality Control in Pharmaceutical Industry. In Advances in economics, business and management research/Advances in Economics, Business and Management Research. Atlantis Press. https://doi.org/10.2991/aebmr.k.220306.047.
20. Zsidisin, G. A., Ellram, L. M., Carter, J. R., & Cavinato, J. L. (2004). An analysis of supply risk assessment techniques. In International Journal of Physical Distribution & Logistics Management (Vol. 34, Issue 5, p. 397). Emerald Publishing Limited. https://doi.org/10.1108/09600030410545445.